Faisal Zain has spent years at the intersection of medical innovation and drug delivery, witnessing firsthand the evolution of how we approach chronic disease. As the biopharmaceutical landscape shifts toward the revolutionary concept of “immune resetting,” he provides a unique perspective on how global leaders are pivoting from simple symptom management to potentially curative interventions. In this conversation, we explore the strategic underpinnings of recent multi-billion dollar acquisitions and the technical challenges of bringing T cell engagers from the oncology ward to the immunology clinic.
Our discussion centers on the mechanics of bispecific antibodies and their ability to recalibrate the body’s defense systems by targeting specific proteins like BCMA and CD19. We delve into the clinical nuances of treating rare conditions such as myasthenia gravis, the financial bravery required to break existing merger agreements for better opportunities, and the operational hurdles of integrating diverse therapeutic platforms. Finally, we look at the competitive pressure to establish a new gold standard in a market currently dominated by high-revenue chronic treatments.
T cell engagers were originally developed for oncology, but are now being adapted to treat autoimmune conditions like myasthenia gravis. What specific physiological changes occur during an “immune system reset,” and how do you measure whether the newly generated B cells are truly non-pathogenic?
The concept of an immune reset is essentially an aggressive spring cleaning of the body’s white blood cell population. When we use T cell engagers like cizutamig, we are essentially using a molecular bridge to bring a patient’s own T cells into direct contact with disease-driving B cells, forcing the T cells to eliminate the pathogenic ones. Once these problematic B cells are depleted, the bone marrow begins to repopulate the system with a fresh generation of cells. We measure the success of this reset by tracking the absence of the specific autoantibodies that cause the symptoms of myasthenia gravis, while simultaneously monitoring for a diverse and healthy B cell repertoire. The goal is to see a clinical environment where the new cells no longer recognize the body’s own tissue as an enemy, a shift we hope to see reflected in long-term Phase 2 data.
Cizutamig targets the BCMA protein while other candidates focus on CD19. What are the clinical trade-offs when selecting one B cell target over another, and how does the choice of target influence the long-term durability of the treatment in patients with interstitial lung disease?
Choosing between BCMA and CD19 is like choosing whether to clear out a specific department or the entire warehouse. BCMA is predominantly expressed on plasma cells and late-stage B cells, which are often the primary factories for the harmful antibodies found in conditions like interstitial lung disease. By targeting BCMA with an asset like cizutamig, you are taking a more surgical approach to the cells most responsible for the disease’s progression. On the other hand, CD19 is found across a much broader range of the B cell lineage, which might offer a more comprehensive “clearance” but could also lead to more significant temporary immunosuppression. The durability of the treatment depends on whether the “reset” prevents the return of the specific pathogenic clones; for a patient struggling with lung fibrosis, the precision of a BCMA target might offer a more favorable safety profile over multiple years.
The current market for immunology involves both chronically dosed antibodies and these newer, potentially curative bispecific therapies. How should a company balance a portfolio between high-revenue daily treatments and one-time interventions that aim for total remission, and what does this shift mean for traditional drug pricing models?
It is a delicate balancing act that requires a company to protect its current bread and butter while investing heavily in the “disruptors” of tomorrow. Take a firm like UCB, which sees roughly €2.2 billion—or about $2.5 billion—in annual sales from a single chronic drug like Bimzelx; that revenue provides the essential dry powder needed for a $2 billion upfront acquisition of a startup like Candid. Moving toward one-time interventions requires a total rethink of the financial model, shifting from a recurring subscription-like revenue stream to a high-value, front-loaded payment system. We are seeing a strategic shift where the €7.4 billion in total net sales generated by traditional portfolios is being used to fund a future where “remission” replaces “management” as the primary product. This transition is risky, but it is the only way to avoid being left behind by more agile biotech competitors.
Consolidating multiple bispecific platforms through various acquisitions allows for a diversified approach to B cell-related diseases. What operational challenges arise when integrating different T cell engager technologies from multiple biotech partners, and how do you ensure these assets do not cannibalize each other’s clinical utility?
The primary challenge is harmonizing different manufacturing standards and clinical protocols that were developed in isolation. When you combine an $80 million deal for an Antengene asset with a multi-billion dollar acquisition of Candid’s pipeline, you have to manage different T cell binding affinities and safety profiles simultaneously. To prevent cannibalization, a company must be very disciplined about “slicing” the market, perhaps directing one TCE toward myasthenia gravis and another toward systemic lupus erythematosus. You also have to manage the potential for milestone payments—which can reach as high as $1.1 billion in some cases—to ensure that you are rewarding the teams for genuine innovation rather than just overlapping results. It is about creating a platform-driven strategy where each asset has a clear, unique path to the patient.
Breaking a prior merger agreement to pursue a larger acquisition involves significant termination fees and regulatory hurdles. When a firm decides to pivot its entire corporate strategy toward a new therapeutic class like immune resetting, what are the primary financial and logistical steps required to close such a complex deal?
A pivot of this magnitude starts with a cold, hard look at the opportunity cost of staying the current course. In the case of Candid, they had to walk away from a merger with Rallybio, a move that triggered a $50 million termination fee payable almost immediately. Beyond that initial penalty, the acquiring firm has to mobilize billions in capital—$2 billion up front in this instance—and prepare for an additional $200 million in milestone-related outlays. Logistically, you have to navigate the regulatory “muster” during a tight window, often aiming to close between the late second quarter and early third quarter. It requires an incredible amount of legal and financial coordination to ensure that the transition from a private startup to a subsidiary of a multi-billion dollar global entity happens without losing the momentum of the ongoing clinical trials.
Several major pharmaceutical companies are currently racing to post Phase 1 and Phase 2 data for autoimmune TCEs. Beyond basic safety and tolerability, what specific metrics will determine which candidate becomes the gold standard, and how will the speed of enrollment impact the competitive landscape over the next eighteen months?
The gold standard will be determined by “depth of depletion” and the “duration of drug-free remission.” We aren’t just looking for safety anymore; we are looking for how quickly the B cells disappear and how long the patient can go without needing a second dose. With competitors like Gilead paying $1.7 billion for their own TCE programs and companies like Cullinan targeting rheumatoid arthritis, the pressure to enroll patients is immense. If a company can post definitive data in the first half of this year, they can capture the market’s imagination and secure the best clinical sites before the field becomes oversaturated. Speed is a currency in this environment, and the winners will be those who can prove their therapy isn’t just a temporary fix but a permanent solution.
What is your forecast for the future of immune system reset therapies?
I believe we are entering an era where the very definition of “chronic disease” will be challenged by these one-time reset technologies. Over the next five to ten years, I expect the industry to move away from the €2.2 billion-a-year chronic antibody model and toward a paradigm where a single infusion of a T cell engager provides years of disease-free living. We will likely see a wave of consolidation as mid-sized firms realize they cannot compete without a “reset” asset in their portfolio, leading to even more aggressive deals than the $2 billion we saw this week. Ultimately, the successful companies will be those that master the manufacturing complexity of these bispecifics, making them as accessible and safe as the biologics we use today. It is an incredibly hopeful time for patients who have spent decades managing symptoms rather than seeking a cure.
